Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel
NASDAQ:XOMA

XOMA Royalty Q1 2025 Earnings Report

XOMA Royalty logo
$41.60 -0.06 (-0.14%)
Closing price 04:00 PM Eastern
Extended Trading
$41.60 +0.00 (+0.01%)
As of 04:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

XOMA Royalty EPS Results

Actual EPS
$0.06
Consensus EPS
-$0.26
Beat/Miss
Beat by +$0.32
One Year Ago EPS
N/A

XOMA Royalty Revenue Results

Actual Revenue
$15.91 million
Expected Revenue
$6.75 million
Beat/Miss
Beat by +$9.16 million
YoY Revenue Growth
N/A

XOMA Royalty Announcement Details

Quarter
Q1 2025
Date
5/13/2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
7:30AM ET

Upcoming Earnings

XOMA Royalty's Q1 2026 earnings is estimated for Tuesday, May 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, May 15, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

XOMA Royalty's Q1 2025 Press ReleasePress Release
(8-K)
XOMA Royalty's Q1 2025 Quarterly reportQuarterly report
(10-Q)

XOMA Royalty Earnings Headlines

XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA
April 28, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/04/28/10373030.htm
Royalty powerhouse: Ligand and Xoma unite in $739 million deal
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/royalty-powerhouse-ligand-and-xoma-unite-in-739-million-deal/ar-AA21PgfV
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.tc pixel
May 6 at 1:00 AM  |  Brownstone Research (Ad)
$XOMA stock is up 9% today. Here's what we see in our data.
April 27, 2026  |  quiverquant.comQ
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation
April 27, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/alert-rowley-law-pllc-is-investigating-proposed-acquisition-of-xoma-royalty-corporation-302754588.html
Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million
April 27, 2026  |  benzinga.comhttps://www.benzinga.com/m-a/26/04/52072759/ligand-bets-on-royalty-growth-with-xoma-buyout-worth-over-700-million
See More XOMA Royalty Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XOMA Royalty? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XOMA Royalty and other key companies, straight to your email.

About XOMA Royalty

XOMA Royalty (NASDAQ:XOMA) (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases. XOMA Royalty partners with biopharmaceutical companies across North America, Europe and other key markets, supporting the continued development and commercialization of innovative treatments. Its due-diligence process emphasizes assets with compelling clinical data, robust intellectual property protection and clear regulatory pathways.

Led by a management team with extensive experience in pharmaceutical finance, licensing and royalty management, XOMA Royalty leverages industry relationships to source and structure transactions. The board comprises executives and advisors with backgrounds in drug development, investment banking and asset management, positioning the company to identify high-quality royalty opportunities and steward its growing portfolio over time.

View XOMA Royalty Profile
Earnings Tools